search
Back to results

Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA)

Primary Purpose

Pain

Status
Recruiting
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
sufentanil
Sponsored by
More Foundation
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pain focused on measuring pain, length of stay, peri-operative, THA, TKA

Eligibility Criteria

50 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adults 50 to 80 years, inclusive
  2. Planned primary THA or TKA
  3. Expressed willingness to be discharged the same day of surgery if condition allows
  4. American Society of Anesthesiologists (ASA) physical classes I - III

    1. ASA I: A normal healthy patient. Example: Fit, nonobese (BMI under 30), a nonsmoking patient with good exercise tolerance.
    2. ASA II: A patient with a mild systemic disease. Example: Patient with no functional limitations and a well-controlled disease (e.g., treated hypertension, obesity with BMI under 35, frequent social drinker or is a cigarette smoker).
    3. ASA III: A patient with a severe systemic disease that is not life-threatening. Example: Patient with some functional limitation as a result of disease (e.g., poorly treated hypertension or diabetes, morbid obesity, chronic renal failure, a bronchospastic disease with intermittent exacerbation, stable angina, implanted pacemaker).
  5. Patients who are English competent.

Exclusion Criteria:

  1. Opioid tolerant (> 50 mg oral morphine milligram equivalents (MMEs) daily)
  2. Current IV drug abuse
  3. History of alcoholism
  4. History of severe renal impairment
  5. History of severe hepatic impairment
  6. Dependent on supplemental oxygen at home
  7. Pregnant
  8. Incarcerated
  9. Patient unable to provide informed consent
  10. Patients undergoing bilateral TKA, THA
  11. Patient undergoing unicompartmental knee arthroplasty (UKA)
  12. Patients undergoing other concurrent surgery
  13. Patients with a history of allergy to any drugs in the study.

Sites / Locations

  • The CORE Institute Specialty HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

No Intervention

Arm Label

Treatment

Control

Arm Description

One dose of sufentanil 30 mcg sublingual will be given pre-operatively when entering the operating room and one dose post-operatively in the PACU in addition to standard of care pain management.

A multimodal approach to analgesia will be used in all subjects in the perioperative setting and will be used in both the control and treatment groups. Intraoperative dosing of opioids will be based on the anesthesiologist's clinical judgement related to the pain and hemodynamic response to surgical stimuli and on an as needed basis in the PACU. Administration of opioids in the PACU will be in response to moderate-to-severe pain.

Outcomes

Primary Outcome Measures

Length of stay
length of hospital stay
Discharge location
Discharged from the PACU instead of the Medical-Surgical Unit

Secondary Outcome Measures

morphine milligram equivalent (MME) doses
the amount of MME doses received
side effect(s)
opioid related side effects
physical therapy
ability to complete physical therapy in PACU
patient satisfaction
patient reported satisfaction of pain management on a 4-point Likert scale with a higher score being more satisfied
hospital costs
total hospital costs

Full Information

First Posted
January 27, 2022
Last Updated
March 29, 2022
Sponsor
More Foundation
search

1. Study Identification

Unique Protocol Identification Number
NCT05307341
Brief Title
Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA)
Official Title
Improving Pain Management and Decreasing Length of Stay After THA and TKA: A Randomized, Patient-Blinded Comparison of Standard of Care Pain Management With and Without Sufentanil
Study Type
Interventional

2. Study Status

Record Verification Date
March 2022
Overall Recruitment Status
Recruiting
Study Start Date
March 2022 (Anticipated)
Primary Completion Date
June 2023 (Anticipated)
Study Completion Date
June 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
More Foundation

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This two arm, patient blinded, randomized, post market clinical trial in a single orthopedic hospital will determine whether there is improved pain management and decreased length of stay when comparing standard of care pain management with and without sufentanil.
Detailed Description
This two arm, patient blinded, randomized, post market clinical trial in a single orthopedic hospital will determine whether there is improved pain management and decreased length of stay (LOS) when comparing standard of care pain management with and without sufentanil. The objective is to compare LOS between patients who have had primary THA or TKA and have received standard of care peri-operative pain management and one dose of sufentanil 30 mcg sublingual pre-operatively in the operating room and one dose post-operatively in the post anesthesia care unit (PACU) versus those who have received only standard of care peri-operative pain management in a orthopedic specialty hospital.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pain
Keywords
pain, length of stay, peri-operative, THA, TKA

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
two arm, patient blinded, randomized, post market
Masking
Participant
Masking Description
participant will not be informed whether participant is in the standard of care arm or treatment arm.
Allocation
Randomized
Enrollment
100 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Treatment
Arm Type
Active Comparator
Arm Description
One dose of sufentanil 30 mcg sublingual will be given pre-operatively when entering the operating room and one dose post-operatively in the PACU in addition to standard of care pain management.
Arm Title
Control
Arm Type
No Intervention
Arm Description
A multimodal approach to analgesia will be used in all subjects in the perioperative setting and will be used in both the control and treatment groups. Intraoperative dosing of opioids will be based on the anesthesiologist's clinical judgement related to the pain and hemodynamic response to surgical stimuli and on an as needed basis in the PACU. Administration of opioids in the PACU will be in response to moderate-to-severe pain.
Intervention Type
Drug
Intervention Name(s)
sufentanil
Other Intervention Name(s)
sufentanil (DSUVIA)
Intervention Description
One dose of sufentanil 30 mcg sublingual pre-operatively upon entry to operating room and one dose of sufentanil 30 mcg sublingual in the PACU.
Primary Outcome Measure Information:
Title
Length of stay
Description
length of hospital stay
Time Frame
From date and time of hospital admission until date and time of hospital discharge, assessed up to 3 days after hospital admission
Title
Discharge location
Description
Discharged from the PACU instead of the Medical-Surgical Unit
Time Frame
At date of discharge from hospital, assessed up to 3 days after hospital admission
Secondary Outcome Measure Information:
Title
morphine milligram equivalent (MME) doses
Description
the amount of MME doses received
Time Frame
From date and time of hospital admission until date and time of hospital discharge, assessed up to 3 days after hospital admission
Title
side effect(s)
Description
opioid related side effects
Time Frame
From date and time of hospital admission until date and time of hospital discharge, assessed up to 3 days after hospital admission
Title
physical therapy
Description
ability to complete physical therapy in PACU
Time Frame
From admission date and time in PACU until discharge date and time from PACU, assessed for 12 hours after surgery
Title
patient satisfaction
Description
patient reported satisfaction of pain management on a 4-point Likert scale with a higher score being more satisfied
Time Frame
At date and time of discharge from the hospital, within 3 days following hospital admission
Title
hospital costs
Description
total hospital costs
Time Frame
From date of hospital admission until date of hospital discharge, assessed for 3 days following hospital admission

10. Eligibility

Sex
All
Minimum Age & Unit of Time
50 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adults 50 to 80 years, inclusive Planned primary THA or TKA Expressed willingness to be discharged the same day of surgery if condition allows American Society of Anesthesiologists (ASA) physical classes I - III ASA I: A normal healthy patient. Example: Fit, nonobese (BMI under 30), a nonsmoking patient with good exercise tolerance. ASA II: A patient with a mild systemic disease. Example: Patient with no functional limitations and a well-controlled disease (e.g., treated hypertension, obesity with BMI under 35, frequent social drinker or is a cigarette smoker). ASA III: A patient with a severe systemic disease that is not life-threatening. Example: Patient with some functional limitation as a result of disease (e.g., poorly treated hypertension or diabetes, morbid obesity, chronic renal failure, a bronchospastic disease with intermittent exacerbation, stable angina, implanted pacemaker). Patients who are English competent. Exclusion Criteria: Opioid tolerant (> 50 mg oral morphine milligram equivalents (MMEs) daily) Current IV drug abuse History of alcoholism History of severe renal impairment History of severe hepatic impairment Dependent on supplemental oxygen at home Pregnant Incarcerated Patient unable to provide informed consent Patients undergoing bilateral TKA, THA Patient undergoing unicompartmental knee arthroplasty (UKA) Patients undergoing other concurrent surgery Patients with a history of allergy to any drugs in the study.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marc Jacofsky, PhD
Phone
623.537.5642
Email
marc.jacofsky@more-foundation.org
First Name & Middle Initial & Last Name or Official Title & Degree
John Thompson, MD
Phone
866.974.2673
Email
john.thompson@thecoreinstitute.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Debra Sietsema, PhD
Organizational Affiliation
More Foundation
Official's Role
Study Director
Facility Information:
Facility Name
The CORE Institute Specialty Hospital
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85015
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rona Curphy
Phone
602-795-6020
Email
rona.curphy@thecoreinstitute.com
First Name & Middle Initial & Last Name & Degree
John Thompson, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Improving Pain Management and Decreasing LOS After Total Hip Arthroplasty (THA) and Total Knee Arthroplasty (TKA)

We'll reach out to this number within 24 hrs